No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred reperfusion strategy is primary percutaneous coronary intervention (PCI). The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients STEMI. In recent years, mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI.